Sign In
Buy INSM
$106.92
-0.490 (-0.456%)
At Close: Jul 24, 2026
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
01:21pm, Wednesday, 29'th May 2024
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Insmed CEO on lung disease treatment and path forward
06:40pm, Tuesday, 28'th May 2024
Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.
Insmed Announces Proposed $500 Million Public Offering of Common Stock
06:21pm, Tuesday, 28'th May 2024
BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Stock More Than Doubled in Value Tuesday—Here's Why
05:25pm, Tuesday, 28'th May 2024
Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study of its experimental drug to reduce symptoms in patients wit
Chart of the Day: Insmed
01:40pm, Tuesday, 28'th May 2024
Michelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.
Insmed shares skyrocket on positive trial results for lung drug
12:36pm, Tuesday, 28'th May 2024
Insmed Incorporated (NASDAQ:INSM) shares more than doubled after the company released positive results from its late-stage study of its experimental therapy brensocatib for a lung condition. The compa
Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)
12:10pm, Tuesday, 28'th May 2024
Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ra
Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market
09:04am, Tuesday, 28'th May 2024
Insmed stock catapulted Tuesday after the biotech company experimental lung disease treatment succeeded in a final-phase study.
Why Is Insmed (INSM) Stock Up 134% Today?
08:40am, Tuesday, 28'th May 2024
Insmed (NASDAQ: INSM ) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis.
Insmed's stock rockets toward a 2-decade high after positive drug-trial data
07:06am, Tuesday, 28'th May 2024
Shares of Insmed Inc. skyrocketed Tuesday, after the biopharmaceutical company said it plans to file a New Drug Application for its treatment of non-cystic fibrosis bronchiectasis following positive P
Insmed's lung disease drug succeeds in late-stage study
06:54am, Tuesday, 28'th May 2024
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study, prompting its shares to double i
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
06:30am, Tuesday, 28'th May 2024
—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Pl
Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
04:00pm, Monday, 27'th May 2024
—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET— BRIDGEWATER, N.J. , May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical compa
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
04:28pm, Monday, 20'th May 2024
—Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
12:15pm, Friday, 10'th May 2024
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
